The study was supported by Alba Therapeutics. Dr. Murray reported serving as a consultant to or on the advisory boards of nearly a dozen pharmaceutical companies, Alba not among them. Dr. Lebwohl reported having no financial conflicts.
Conference Coverage
Larazotide eased symptoms in phase II celiac trial
More IBD & Intestinal Disorders News
- Does Bezlotoxumab Boost FMT Efficacy in IBD Patients With Recurrent CDI?
- Angiotensin Receptor Blockers May Lead to Worse Outcomes in Celiac Disease
- Common Crohn’s Immune Response to Gut Bacteria Suggests Therapeutic Target
- Guselkumab Efficacy in Crohn’s Disease Unaffected by Prior Biologic Use
- IBS: Understanding a Common Yet Misunderstood Condition
- Breath Gas Patterns Predict Response to Low FODMAP Diet
- Ultraprocessed Foods Associated With Relapse Risk in Crohn’s Disease
- Live Rotavirus Vaccine Safe for Newborns of Biologic-Treated Moms With IBD
Question 1 of 5